Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, BVXVW; TASE: BVXV) covers the month of August 2015, with the report dated August 10, 2015. The registrant is a foreign private issuer based in Ness Ziona, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding corporate governance and does not contain financial statements.
Material Changes
The primary material event reported is the postponement of three Extraordinary General Meetings (EGMs) for holders of tradable options (Series 3, Series 4, and Series 5). The meetings were originally scheduled but were delayed by one week due to the absence of a quorum.
Outlook, Risks, and Management Commentary
Management has rescheduled the postponed EGMs to August 16, 2015, at the law office of Pearl Cohen Zedek Latzer Baratz in Tel Aviv. The specific times for the meetings are:
- Series 3 Options: 09:00 a.m. (Israel Time)
- Series 4 Options: 10:00 a.m. (Israel Time)
- Series 5 Options: 11:00 a.m. (Israel Time)
The record date for all three meetings remains July 27, 2015. No other risks, contingencies, or unusual items were disclosed in this text.
Key Facts for Investor Verification
- Verify the new meeting dates and times for Series 3, 4, and 5 option holders on August 16, 2015.
- Confirm the record date of July 27, 2015, to determine eligibility to vote at the rescheduled meetings.
- Check subsequent filings to determine if the quorum was achieved at the rescheduled meetings and what resolutions were passed.